区分持续性分化型甲状腺癌与复发性分化型甲状腺癌:不同情况不同结局
该回顾性分析纳入4292例分化型甲状腺癌(DTC)患者,平均随访6.5年,比较持续性病变与复发性病变的患病率及结局。结果显示14.9%患者初始治疗后出现疾病事件,其中78%为持续性病变,22%为复发性病变;持续性病变患者年龄更大、男性比例更高、远处转移更常见,且多因素分析中男性、年龄、滤泡型、T3、N1b与持续性病变独立相关,仅N1b与复发性病变相关。
要点
- DTC初始治疗后疾病事件中持续性病变占多数,且结局较复发性病变更差。
- 持续性病变患者远处转移比例显著高于复发性病变(38.4% vs 17.0%)。
- N1b与持续性和复发性病变均独立相关,男性、年龄、滤泡型、T3仅与持续性病变相关。
核心结论
- 在初始治疗后未治愈的DTC患者中,持续性病变比复发性病变更常见且结局更差。
- 术后第一年随访评估的状态可能对制定个体化治疗策略和长期随访方案有重要临床意义。
研究设计与样本
- 回顾性分析1990年至2016年三级甲状腺癌转诊中心的DTC患者,平均随访6.5年。
- 共纳入4292例接受手术±131I治疗的DTC患者,评估持续性/复发性疾病。
主要发现
- 4292例中639例(14.9%)初始治疗后出现疾病事件,其中498例(78%)为持续性病变,141例(22%)为复发性病变。
- 持续性病变患者较复发性病变患者年龄更大(平均46.9 vs 45.7岁),女性/男性比更低(1.9/1 vs 4.8/1)。
- 持续性病变患者结构化疾病更常见(65.7% vs 41.1%),远处转移显著更常见(38.4% vs 17.0%)。
- 多因素分析中,男性(OR=1.7)、年龄(OR=1.02)、滤泡型(OR=1.5)、T3(OR=3)、N1b(OR=7.7)与持续性病变独立相关。
- 仅N1b(OR=2.5)与复发性病变独立相关。
临床怎么用
- 对DTC初始治疗后未治愈者,应区分持续性病变与复发性病变,持续性病变需更积极评估远处转移。
- 术后第一年随访状态评估有助于识别高危持续性病变患者并制定个体化随访策略。
局限性
- 为单中心回顾性分析,可能存在选择偏倚。
- 平均随访6.5年,复发性病变的长期结局可能未完全捕捉。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Differentiated thyroid cancer (DTC) has an excellent prognosis, but up to 20% of patients with DTC have disease events after initial treatment, indistinctly defined as persistent/recurrent disease. OBJECTIVE: To evaluate the prevalence and outcome of "recurrent" disease (relapse after being 12 months disease-free) compared with "persistent" disease (present ab initio since diagnosis). DESIGN: Retrospective analysis of persistent/recurrent disease in patients with DTC (1990 to 2016) with 6.5 years of mean follow-up. SETTING: Tertiary referral center for thyroid cancer. PATIENTS: In total, 4292 patients all underwent surgery ± 131I treatment of DTC. MAIN OUTCOME MEASURES: DTC cure of disease persistence or recurrence. RESULTS: A total of 639 of 4292 (14.9%) patients had disease events after initial treatment, most (498/639, 78%) with persistent disease and 141 (22%) with recurrent disease. Relative to patients with recurrent disease, patients with persistent disease were significantly older (mean age 46.9 vs 45.7 years) and with a lower female to male ratio (1.9/1 vs 4.8/1). Moreover, in this group, structured disease was more frequent (65.7% vs 41.1%), and more important, distant metastases were significantly more frequent (38.4% vs 17.0%). At multivariate analysis, male sex (OR = 1.7), age (OR = 1.02), follicular histotype (OR = 1.5), T status (T3; OR = 3), and N status (N1b; OR = 7.7) were independently associated with persistent disease. Only the N status was associated with recurrent disease (N1b; OR = 2.5). CONCLUSIONS: In patients with DTC not cured after initial treatment, persistent disease is more common and has a worse outcome than recurrent disease. Postoperative status evaluated during first-year follow-up may have important clinical implications for planning tailored treatment strategies and long-term follow-up procedures.
引用
- Sapuppo G, Tavarelli M, Belfiore A, et al. Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes. J Clin Endocrinol Metab. 2019. PMID: 30165559. doi:10.1210/jc.2018-01383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。